Literature DB >> 23301842

Clinical significance of overexpressed cyclin-dependent kinase subunits 1 and 2 in esophageal carcinoma.

J-J Wang1, Z-X Fang, H-M Ye, P You, M-J Cai, H-B Duan, F Wang, Z-Y Zhang.   

Abstract

The mammalian cyclin-dependent kinase subunit (Cks) family has two members, Cks1 and Cks2. Overexpression of Cks1 and Cks2 has been reported to be associated with high aggressiveness and poor prognosis in several malignancies, including prostate and hepatocellular carcinomas. However, whether Cks1 and Cks2 are overexpressed in esophageal carcinoma remains uncharacterized. To investigate whether overexpression of the Cks family is clinically relevant in esophageal carcinoma, and whether expression patterns of Cks1 and Cks2 can serve as biomarkers for esophageal carcinoma. Real-time quantitative reverse transcription polymerase chain reaction, immunohistochemistry, and Western blot analyses were applied to detect the expression of Cks1 and Cks2 at the mRNA and protein levels, respectively. The associations between Cks1 or Cks2 expressions and clinical features and p27(kip1) expressions in esophageal carcinoma were analyzed. Comparing with the adjacent noncancerous tissues, esophageal carcinoma exhibited elevated expression of Cks1 in 58% cases at the mRNA level and 54% cases at the protein level, and elevated expression of Cks2 in 65% cases at the mRNA level and 61% cases at the protein level, respectively. The expressions of both Cks1 and Cks2 were negatively associated with the p27(kip1) protein level in the tumor tissues. Furthermore, overexpression of Cks1 and Cks2 in esophageal carcinoma was closely associated with poor pathological features of esophageal carcinoma, including higher histologic grade of tumor, regional lymph nodes invasion, and neoplastic embolus. Overexpression of Cks1 and Cks2 is associated with the aggressive tumor behaviors of esophageal carcinoma. Further efforts are needed to determine whether overexpression of Cks1 and Cks2 can serve as novel biomarkers for esophageal carcinoma.
© 2012 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Keywords:  Cks1; Cks2; esophageal carcinoma; p27kip1

Mesh:

Substances:

Year:  2013        PMID: 23301842      PMCID: PMC4797631          DOI: 10.1111/dote.12013

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  19 in total

1.  Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.

Authors:  J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

2.  The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27.

Authors:  D Ganoth; G Bornstein; T K Ko; B Larsen; M Tyers; M Pagano; A Hershko
Journal:  Nat Cell Biol       Date:  2001-03       Impact factor: 28.824

3.  Cyclin E-CDK2 is a regulator of p27Kip1.

Authors:  R J Sheaff; M Groudine; M Gordon; J M Roberts; B E Clurman
Journal:  Genes Dev       Date:  1997-06-01       Impact factor: 11.361

4.  Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe.

Authors:  H E Richardson; C S Stueland; J Thomas; P Russell; S I Reed
Journal:  Genes Dev       Date:  1990-08       Impact factor: 11.361

5.  Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray.

Authors:  Yick-Fu Wong; Tak-Hong Cheung; George S W Tsao; Keith W K Lo; So-Fan Yim; Vivian W Wang; Macy M S Heung; Samuel C S Chan; Loucia K Y Chan; Tina W F Ho; Katherine W Y Wong; Chen Li; Yu Guo; Tony K H Chung; David I Smith
Journal:  Int J Cancer       Date:  2006-05-15       Impact factor: 7.396

6.  Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling.

Authors:  Kazumori Kawakami; Hideki Enokida; Tokushi Tachiwada; Takenari Gotanda; Kengo Tsuneyoshi; Hiroyuki Kubo; Kenryu Nishiyama; Masaki Takiguchi; Masayuki Nakagawa; Naohiko Seki
Journal:  Oncol Rep       Date:  2006-09       Impact factor: 3.906

7.  Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma.

Authors:  Dong-Yan Shen; Zan-Xi Fang; Pan You; Ping-Guo Liu; Fen Wang; Chun-Ling Huang; Xiao-Bin Yao; Zi-Xuan Chen; Zhong-Ying Zhang
Journal:  Liver Int       Date:  2009-10-21       Impact factor: 5.828

8.  Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer.

Authors:  Min Ah Kang; Jong-Tae Kim; Joo Heon Kim; Soo-Young Kim; Young Ho Kim; Young Il Yeom; Younghee Lee; Hee Gu Lee
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-26       Impact factor: 4.553

9.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

10.  Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer.

Authors:  Heidi Lyng; Runar S Brøvig; Debbie H Svendsrud; Ruth Holm; Olav Kaalhus; Kjetil Knutstad; Halldis Oksefjell; Kolbein Sundfør; Gunnar B Kristensen; Trond Stokke
Journal:  BMC Genomics       Date:  2006-10-20       Impact factor: 3.969

View more
  14 in total

1.  Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.

Authors:  Baosheng Zhou; Guoyun Bu; Yipin Zhou; Yue Zhao; Wei Li; Mu Li
Journal:  Med Oncol       Date:  2014-11-30       Impact factor: 3.064

2.  CKS2 in human cancers: Clinical roles and current perspectives (Review).

Authors:  Hanyu You; Huayue Lin; Zhongying Zhang
Journal:  Mol Clin Oncol       Date:  2015-02-04

3.  Expression of cyclin kinase subunit 2 in human breast cancer and its prognostic significance.

Authors:  Jiani Wang; Lihua Xu; Yu Liu; Jianning Chen; Hua Jiang; Shaojiang Yang; Huo Tan
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

4.  Up-regulated CKS2 promotes tumor progression and predicts a poor prognosis in human colorectal cancer.

Authors:  Min-Hao Yu; Yang Luo; Shao-Lan Qin; Zheng-Shi Wang; Yi-Fei Mu; Ming Zhong
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

5.  Cks1: Structure, Emerging Roles and Implications in Multiple Cancers.

Authors:  Vinayak Khattar; Jaideep V Thottassery
Journal:  J Cancer Ther       Date:  2013-10-01

6.  Cks overexpression enhances chemotherapeutic efficacy by overriding DNA damage checkpoints.

Authors:  S V del Rincón; M Widschwendter; D Sun; S Ekholm-Reed; J Tat; L K Teixeira; Z Ellederova; E Grolieres; S I Reed; C Spruck
Journal:  Oncogene       Date:  2014-05-26       Impact factor: 9.867

7.  PSMB8 and PBK as potential gastric cancer subtype-specific biomarkers associated with prognosis.

Authors:  Chae Hwa Kwon; Hye Ji Park; Yu Ri Choi; Ahrong Kim; Hye Won Kim; Jin Hwa Choi; Chung Su Hwang; So Jung Lee; Chang In Choi; Tae Yong Jeon; Dae Hwan Kim; Gwang Ha Kim; Do Youn Park
Journal:  Oncotarget       Date:  2016-04-19

8.  CKS1 expression in melanocytic nevi and melanoma.

Authors:  Anna A Brożyna; Andrew Aplin; Cynthia Cohen; Grant Carlson; Andrew Joseph Page; Michael Murphy; Andrzej T Slominski; J Andrew Carlson
Journal:  Oncotarget       Date:  2017-12-23

9.  Increased expression of Cks1 protein is associated with lymph node metastasis and poor prognosis in nasopharyngeal carcinoma.

Authors:  Lina Xu; Songqing Fan; Jin Zhao; Peng Zhou; Shuzhou Chu; Jiadi Luo; Qiuyuan Wen; Lingjiao Chen; Sailan Wen; Li Wang; Lei Shi
Journal:  Diagn Pathol       Date:  2017-01-07       Impact factor: 2.644

10.  Depletion of Cks1 and Cks2 expression compromises cell proliferation and enhance chemotherapy-induced apoptosis in HepG2 cells.

Authors:  Lingqing Lin; Zanxi Fang; Huayue Lin; Hanyu You; Jiajia Wang; Yuanhui Su; Fen Wang; Zhong-Ying Zhang
Journal:  Oncol Rep       Date:  2015-11-02       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.